pharmaceutical investing Mesoblast Licensee Files for Marketing Approval to Treat Epidermolysis Bullosa
Hercules Capital Provides US$15M From Existing Facility for Mesoblast to Accelerate Product Commercialization Programs
Mesoblast Reports First Quarter Ended September 30, 2018 Financial Results and Operational Highlights
Sun Summit Commences Drilling and Provides Exploration Update from the JD Project in BC's Toodoggone District
